---
title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264500340.md"
datetime: "2025-11-05T21:27:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264500340.md)
  - [en](https://longbridge.com/en/news/264500340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264500340.md)
generator: "portal-rs"
---

# REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.61.

EBIT: As of FY2025 Q3, the actual value is USD -325.92 M.

### Segment Revenue

-   **Research and Development Expenses**: $262.5 million for the three months ended September 30, 2025, compared to $151.8 million for the same period in 2024, representing a 73% increase. For the nine months ended September 30, 2025, expenses were $692.4 million, compared to $404.1 million in 2024, a 71% increase.

### Operational Metrics

-   **Net Loss**: $305.2 million for the three months ended September 30, 2025, compared to $156.3 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $766.4 million, compared to $405.5 million in 2024.
-   **General and Administrative Expenses**: $52.8 million for the three months ended September 30, 2025, compared to $24.0 million for the same period in 2024, representing a 120% increase. For the nine months ended September 30, 2025, expenses were $128.4 million, compared to $69.1 million in 2024, an 86% increase.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $623.5 million for the nine months ended September 30, 2025, compared to - $419.1 million for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: $43.2 million for the nine months ended September 30, 2025, compared to - $161.5 million in 2024.
-   **Net Cash Provided by Financing Activities**: $255.9 million for the nine months ended September 30, 2025, compared to $85.6 million in 2024.

### Unique Metrics

-   **Liability Related to Sale of Future Royalties**: $256.5 million as of September 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is advancing a deep pipeline of RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, with plans to initiate several Phase 3 registrational trials in 2025 and 2026.
-   **Non-Core Business**: The company has entered into collaborations with Tango Therapeutics, Summit Therapeutics, and others to explore combination therapies and novel treatment approaches.

### Priority

-   The company emphasizes the development of RAS(ON) inhibitors and plans to initiate multiple pivotal trials, including the RASolute 302 study and RASolve 301 study, with expected clinical readouts in 2026.

### Related Stocks

- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [ANALYSIS-Depleted US oil stash loses potency as Iran war grinds on](https://longbridge.com/en/news/297496754.md)
- ['This Changes Everything,' Says Investor About Palantir Stock](https://longbridge.com/en/news/297515312.md)
- [Nvidia Just Delivered Bad News for AMD and Intel](https://longbridge.com/en/news/297432140.md)
- [The Calmer Co. Details ASX Governance Compliance in Appendix 4G Filing](https://longbridge.com/en/news/297454626.md)
- [So-Young International (NASDAQ:SY) Announces Earnings Results](https://longbridge.com/en/news/297511012.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**